Physician profile
David R Allen
NPI 1154398410
$991.73
in general payments reported to CMS, 2019-2025
14 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.81 · 2020: $136 · 2021: $164 · 2022: $70.88 · 2023: $215 · 2024: $232 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $317.99 | 2019-2025 | Fasenra |
| Glaxosmithkline, LLC. | $180.99 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $97.62 | 2024 | |
| Mylan Specialty L.P. | $75.29 | 2023-2024 | Yupelri |
| United Therapeutics Corporation | $66.21 | 2023-2024 | Tyvaso |
| Abbvie INC. | $59.34 | 2022-2023 | Vraylar |
| Abbott Laboratories | $52.54 | 2023 | Ensite, Aveir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.62 | 2019-2021 | |
| Genentech USA, INC. | $26.91 | 2019-2020 | |
| Viatris Specialty LLC | $22.80 | 2025 | Yupelri |
| Philips North America LLC | $17.07 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.30 | 2021 | |
| Novo Nordisk INC | $13.80 | 2020 | |
| Pfizer INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.